CVT And Gilead Look To Lock Out Astellas With Planned Merger
This article was originally published in PharmAsia News
Executive Summary
Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion